Medical Oncology Department, Istituto Oncologico Veneto/IRCCS, Via Gattamelata 64, 35128 Padova, Italy.
Anticancer Res. 2010 Sep;30(9):3817-21.
This was a phase II study to assess the activity of a novel neoadjuvant regimen in locally-advanced breast cancer.
Fifty patients with histological confirmation of locally advanced breast cancer received treatment with gemcitabine 1000 mg/m(2) (day 1) followed by gemcitabine 800 mg/m(2) plus docetaxel 75 mg/m(2) plus pegylated liposomal doxorubicin (PLD) 30 mg/m(2) (day 8) every 3 weeks for at least 4 cycles, plus a final 2 additional cycles. Tumour size was T1 (n=2), T2 (n=32), T3 (n=14), T4 (n=2). All 50 patients underwent surgery.
Clinical complete, partial and no response were observed in 13 (26%), 24 (48%) and 11 (22%) patients, respectively (overall response rate: 74%). The number of chemotherapy cycles was found to be an independent predictor of a pathologic complete response.
The combination of gemcitabine-docetaxel-PLD can yield high tumour response rates in patients with locally-advanced breast cancer who undergo a full treatment of 6 cycles.
这是一项评估新辅助方案治疗局部晚期乳腺癌疗效的 II 期研究。
50 例组织学证实为局部晚期乳腺癌患者接受治疗，方案为吉西他滨 1000mg/m²（第 1 天），随后为吉西他滨 800mg/m²联合多西他赛 75mg/m²联合聚乙二醇化脂质体阿霉素（PLD）30mg/m²（第 8 天），每 3 周为一个周期，至少进行 4 个周期，再加上最后 2 个周期。肿瘤大小为 T1（n=2）、T2（n=32）、T3（n=14）、T4（n=2）。所有 50 例患者均接受了手术。
13 例（26%）、24 例（48%）和 11 例（22%）患者分别观察到临床完全缓解、部分缓解和无缓解（总缓解率：74%）。化疗周期数是病理完全缓解的独立预测因素。
吉西他滨-多西他赛-PLD 联合方案可使接受完整 6 个周期治疗的局部晚期乳腺癌患者获得较高的肿瘤缓解率。
